2020
DOI: 10.1016/j.lfs.2020.117631
|View full text |Cite
|
Sign up to set email alerts
|

Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: A review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
30
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 60 publications
(30 citation statements)
references
References 72 publications
0
30
0
Order By: Relevance
“…42 Selective inhibitors of COX-2 are known to increase the risk of cardiotoxicity. 43 Valdecoxib is a selective COX-2 inhibitor with less effect on platelet aggregation and displays bridged gastrointestinal complications. 44,45 Arachidonic acid is a natural substrate that is metabolized to both pro-inflammatory and anti-inflammatory eicosanoids during and after the inflammatory response, respectively.…”
Section: Discussionmentioning
confidence: 99%
“…42 Selective inhibitors of COX-2 are known to increase the risk of cardiotoxicity. 43 Valdecoxib is a selective COX-2 inhibitor with less effect on platelet aggregation and displays bridged gastrointestinal complications. 44,45 Arachidonic acid is a natural substrate that is metabolized to both pro-inflammatory and anti-inflammatory eicosanoids during and after the inflammatory response, respectively.…”
Section: Discussionmentioning
confidence: 99%
“…It is because of possible detrimental impacts on the heart and possible fatal consequences that every drug during pre-clinical development must be tested for cardiotoxicity [ 147 , 195 ]. Cardiotoxicity remains a major decision factor for success or failure in clinical drug development and successful marketing (e.g., in the case of the COX-2 inhibitor rofecoxib for arthritis [ 196 , 197 , 198 , 199 , 200 ]).…”
Section: Myofilaments and Ca 2+ Responsivenessmentioning
confidence: 99%
“…This extra pocket fits the butterfly shaped COX‐2 inhibitors absolutely into the V‐shaped binding pocket. However, this butterfly shape is accountable for the cardiotoxicity of selective COX‐2 inhibitors [12] . Selective COX‐2 inhibitors reduce vasodilatory prostaglandin synthesis leading to renal ischemia by promoting sodium retention and causing altered systolic and diastolic blood pressure, which in due course leads to cardiac problems [13] .…”
Section: Introductionmentioning
confidence: 99%